baber/WOPTO huggingface dataset:
Patent PT-1451196-E (PT)
Title: The use of substituted tetracyclic imidazole derivatives as anti-histaminics
Inventor: JANSSENS FRANS EDUARD
IPC: A61P37/08
Filed: 2002-11-22
Abstract: The invention concerns the use of an H1- and/or H2-histamine receptor antagonist for the reduction of intracranial pressure (ICP), in particular for the prevention and treatment of elevated intracranial pressure and/or secondary ischaemia, in particular caused by brain injury, more in particular caused by traumatic (TBI) and non-traumatic brain injury. In particular, the histamine antagonist is selected from the group of acrivastine, alimemazine, antazoline, astemizole, azatadine, azelastine, brompheniramine, buclizine, carbinoxamine, carebastine, cetirizine, chlorcyclizine, chlorpheniramine, cinnarizine, clemastine, clemizole, clocinizine, clonidine, cyclizine, cyproheptadine, descarboethoxyloratidine, dexchlorpheniramine, dimenhydrinate, dimethindene, dimethothiazine, diphenhydramine, diphenylpyraline, doxylamine, ebastine, efletirizine, epinastine, fexofenadine, hydroxyzine, ketotifen, levocabastine, loratidine, meclizine, mequitazine, methdilazine, mianserin, mizolastine, niaprazine, noberastine, norastemizole, oxatomide, oxomemazine, phenbenzamine, pheniramine, picumast, promethazine, pyrilamine, temelastine, terfenadine, trimeprazine, tripelennamine, triprolidine, ranitidine, cimetidine, famotidine, nizatidine, tiotidine, zolantidine, ritanserine, and derivatives thereof and mixtures of any two or more of the foregoing.
Patent PT-1474425-E (PT)
Inventor: JANE DAUN
IPC: A61K31/541
Filed: 2003-01-07
Abstract: The present invention provides compounds having formula (I), wherein R 1 , R 2 , R 3  and n are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof in the treatment of inflammatory or autoimmune and proliferative disorders and as inhibitors of cell adhesion molecule expression and inflammatory cytokine signal transduction generally.
Patent PT-1648814-E (PT)
Title: Process for producing a mattress
Inventor: YEN ODD SLETTA
IPC: B68G11/04
Filed: 2004-07-15
Abstract: The present invention relates to process for the manufacturing of mattresses characterized in that a liquid molding substance of the same material as the construction pieces (1, 3, 4, 6) is used in all the joints between the pieces. The process comprises steps wherein: the bottom piece (1) is laid out; the molding substance (2) is applied to the longitudinal edges (3) and cross edges (4) on one surface side of the bottom piece (1); the longitudinal pieces (3) and cross pieces (4) are lowered into a molding substance (2) and hardened; the molding substance (2) is applied on the same surface side of the bottom piece (1) between the longitudinal pieces (3) and cross pieces (4); a core (6) is lowered into the molding substance (2) and hardened; and the top piece (7) is provided with molding substance (2) and turned with the molding substance (2) facing the named upright longitudinal pieces (3) and cross pieces (4) and lowered onto the same and hardened.
Patent PT-1706210-E (PT)
Title: Device for holding a fluidic component
Inventor: HAUSMANN MATTHIAS
IPC: B05B1/00
Filed: 2004-12-28
Abstract: A fluidic component is arranged in an elastomeric shaped part the contour of which is matched to the outer contour of the component and to the inner contour of a holder. The elastomeric shaped part is chamfered towards the fluidic component on its pressure side. When the holder is assembled the elastomeric shaped part is deformed by a projection provided on a mating part and is put under uniformly distributed internal tension, after which the elastomeric shaped part surrounds the fluidic component to its full height.
Patent PT-1653609-E (PT)
Title: Tv reception headend, with circuit for automatic control of output levels
Inventor: ZAMALLOA RICARDO ISASI
IPC: H03G3/30
Filed: 2005-10-27
Abstract: The reception headend for collective TV or the cable network CATV has a plurality of analogue or digital input signal (120) processing modules (P1-Pn), of the RF tuned channels (CH1-CHn). The TV headend (1) comprises an automatic gain control circuit (AGC) common to all the processors (P1-Pn) governed by a microcontroller (7) for the automatic control of the output levels (L) of all the tuned processors (P1-Pn), including a Vdc voltage generator block (5) that obtains, in collaboration with said microcontroller (7), sequentially and in real time as many voltages Vagc-1 to Vagc-n as processors (P1-Pn) tuned, and a storage memory (8) of the numeric configuration data of the TV headend (1), through which the high precision of the output levels is obtained (L) independently of the adjacent channels (n+3 to n-3).
Patent PT-1809127-E (PT)
Title: Carbonated protein drink and method of making
Inventor: SHERWOOD SHAWN
IPC: A23L2/54
Filed: 2005-10-07
Abstract: An improved carbonated protein beverage/drink composition which provides a relatively high protein content, ranging from about 2% by weight to about 15% by weight, while simultaneously employing a carbonation concentration between about 0.1 volumes of carbonation (per volume of liquid drink solution or liquid drink suspension) to about 4 volumes of carbonation. Preferably the protein is whey protein. The carbonated protein beverage has been heat treated to inactivate microbes in the presence of the carbonation which is used to provide taste and mouth feel for the drink. Typically, the treatment for microbe inactivation is carried out in the individual package used for storage and handling of the carbonated protein drink.
Patent PT-1652920-E (PT)
Title: Methods of producing protein libraries and selection of proteins from them
Inventor: BREITLING FRANK
IPC: C12N15/09
Filed: 2001-10-01
Abstract: Humanizing a hybridoma cell (A) so that the expressed antibody (Ab) is bound to the surface of the cell expressing it, so as to allow detection and selection of those cells that present a humanized constant Ab domain, comprises transfecting the hybridoma cell line with heavy and light chain constant domains, and expanding cells that express Ig heavy chain and kappa or lambda light chain constant regions. Humanizing a hybridoma cell (A) comprises: (a) transfecting the hybridoma cell line with a DNA sequence (I) that encodes one or more of the human constant immunoglobulin (Ig) G, M, A, D or E domains; (b) (I) is flanked by DNA sequences (II) that are homologous with chromosomal gene regions that flank the constant domains of the active heavy chain-encoding gene locus in (a); (c) one or a few cells are expanded that, on the basis of homologous recombination (HR), express an Ig heavy chain with a humanized constant region; (d) a DNA sequence (III), encoding a human constant kappa or lambda domain, is transfected into the cells, where (III) is flanked by sequences (IV) homologous with chromosomal gene regions that flank the constant domain of the active kappa or lambda gene locus in (a); and (e) one or a few cells are expanded that, on the basis of HR, express a kappa or lambda chain having a human constant region. The expressed Ab is bound to the surface of the cell expressing it, through covalent bonding of the membrane-bound splice variant of the heavy chain, making it possible to detect and select those cells that present a human constant antibody domain. Independent claims are also included for: (1) vector that contains one or more of the DNA sequences specified above; and (2) host cell that contains a vector of (1).
Patent PT-1890967-E (PT)
Title: Niobium suboxides
Inventor: SCHNITTER CHRISTOPH
IPC: C01G33/00
Filed: 2006-05-31
Abstract: Disclosed is a niobium suboxide powder for the manufacture of capacitors with higher break down voltages, higher temperatures of operation and elongated lifetimes. The powder is doped with nitrogen which is at least partly present in the form homogeneously distributed, x-ray detectable Nb 2 N-crystal domains.
Patent PT-1898876-E (PT)
Title: Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical presentations
Inventor: BOTTONI GIUSEPPE
IPC: A61K31/415
Filed: 2006-06-01
Abstract: Object of the invention are mucoadhesive and controlled release formulations consisting of aqueous solutions containing 0.05% to 5% by weight of a natural purified polymer having xyloglucan structure and 10% to 70% by weight of glycerol. These formulations are suitable for the application on human mucous membranes, such as nasal, oral and vaginal mucous membranes, as moisturizing and softening agents or as pharmaceutical release system. Further objects of the invention are pharmaceutical formulations and medical devices suitable for the application to human mucous membranes, containing the mucoadhesive and controlled release formulations together with active ingredients and excipients.
Patent PT-1891130-E (PT)
Title: High intrinsic viscosity melt phase polyester polymers with acceptable acetaldehyde generation rates
Inventor: JERNIGAN MARY THERESE
IPC: C08G63/78
Filed: 2006-06-14
Abstract: A method for the production of solid polyester polymer particles comprising: a) polycondensing a molten polyester polymer composition in the presence of a polycondensation catalyst composition comprising antimony species; b) continuing the polycondensation of the molten polyester polymer composition to an It.V. of 0.68 dL/g or more; and c) after reaching an It.V. of 0.68 dL/g or more, adding a catalyst stabilizer or deactivator to the polymer melt; and d) after reaching an It.V. of 0.68 dL/g or more, solidifying the melt into solid polyester polymer particles which do not contain organic acetaldehyde scavengers. In a further embodiment, after solidification of the polyester from the melt phase polycondensation process: e) the amount of residual acetaldehyde in the particles in the solid state is reduced to a level of 10 ppm or less without increasing the It.V. of the particles by more than 0.03 dL/g. Such particles having an AA (acetaldehyde) generation rate of 20 ppm or less upon being melted after solidification following the melt phase production and a free AA level reduced after melt phase production to 10 ppm or less are introduced into a melt processing zone to make articles such as bottle preforms having acceptable levels of residual AA.
Patent PT-2155179-E (PT)
Title: Axomadol for treating pain from arthritis
Inventor: BLOMS-FUNKE PETRA
IPC: A61K31/135
Filed: 2008-05-09
Abstract: The use of axomadol for the treatment of pain in arthrosis.
Patent PT-2183142-E (PT)
Title: Cable transportation system and relative operating method
Inventor: BAVARESCO FEDERICO
IPC: B61B7/02
Filed: 2008-08-04
Abstract: A cable transportation system has a pull cable; at least one transportation unit moving along a given path and connectable selectively to the pull cable by a coupling device; at least one passenger station where the transportation unit is detached from the pull cable; and an auxiliary drive device having a linear electric motor extending along a portion of the given path to move the transportation unit along the passenger station.
Patent PT-2198886-E (PT)
Title: Method for inactivating pathogens in donor blood, blood plasma or erythrocyte concentrates in flexible containers in motion
Inventor: MOHR HARALD
IPC: A61K41/00
Filed: 2006-12-21
Abstract: The method involves filling exposure bag with supplement to less than thirty percent volume of the maximum volume of the exposure bag for photodynamic treatment or irradiation with ultra-violet light. The exposure bag is moved during the photo-dynamic treatment or the irradiation with ultravoilet light, so that contents of the exposure bag are rolled and zones of changing layer thicknesses are formed by the movement. The photoactive substance is a phenotiazines dyestuff, particularly thionin, methylene blue, phthalocyanine, phorphyrin and toluidine blue.
Patent PT-2292230-E (PT)
Title: Tamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
Inventor: MANNION RICHARD OWEN
IPC: A61K9/22
Filed: 2007-08-24
Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.
Patent PT-703228-E (PT)
Inventor: MUEHL BRIAN STEPHEN
IPC: C07D295/08
Filed: 1995-09-18
Abstract: The present invention provides a compound of formula I <CHEM>  wherein R<1> is -H, -OH, -O(C1-C4 alkyl), -OCOC6H5, -OCO(C1-C6 alkyl), or -OSO2(C4-C6 alkyl); R<2> is -H, -OH, -O(C1-C4 alkyl), -OCOC6H5, -OCO(C1-C6 alkyl) or -OSO2(C4-C6 alkyl);     n is 2 or 3; and R<3> is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, or 1-hexamethyleneimino;  or a pharmaceutically acceptable salt thereof. The compounds are useful for treating diseases such as post-menopausal syndrome, and uterine fibroid disease, endometriosis, and aortal smooth muscle cell proliferation.
Patent PT-784603-E (PT)
Inventor: MCCAGUE RAYMOND
IPC: C07D211/60
Filed: 1995-10-09
Abstract: A process for the preparation of optically-enriched pipecolic acid as a salt with an optically-active acid, comprises asymmetric transformation of pipecolic acid, as a racemic mixture or a mixture enriched in the opposite enantiomer from that desired, with the optically-active acid in a solvent comprising an acid that causes racemisation, in the absence of aldehyde.                               00000
Patent PT-828500-E (PT)
Inventor: BOMBARDELLI EZIO
IPC: A61K31/335
Filed: 1995-10-10
Abstract: The invention relates to methods for preventing, inhibiting, or suppressing tumors by administering to a person in need of such treatment a therapeutically effective amount of one or more flavanolignanes, such as silymarin, silybin, silidianin, silicristin, dehydrosilybin, mixtures thereof, or extracts thereof as an antiproliferative. The invention further relates to the antitumor pharmaceutical composition includes a therapeutically effective amount of the flavanolignane selected from the group of silymarin, silybin, silidianin, silicristin, dehydrosilybin, and mixtures thereof, in combination with a different antitumor agent. In another embodiment, the pharmaceutical composition includes a therapeutically effective amount of a flavanolignane selected from the group of silidianin, silicristin, and mixtures thereof, with a pharmaceutically acceptable carrier or excipient. The compositions and method may be prepared or administered with different antitumoral agents for concurrent or sequential use for treating tumors, such as those typically found in the uterus, ovary, and breast.
Patent PT-833669-E (PT)
Inventor: WEERS JEFFRY GREG
IPC: A61K49/22
Filed: 1996-06-05
Abstract: Long lasting gas emulsions for ultrasound and magnetic resonance imaging contrast enhancement utilize low Ostwald coefficient fluoromono- and fluoropolyether compounds. Gas emulsions comprising microbubble preparations are disclosed wherein the microbubbles comprises fluoroethers such as perfluorodiglyme (CF3(OCF2CF2)2OCF3), perfluoromonoglyme (CF3OCF2CF2OCF3), perfluorodiethylether C2F5OC2F5, perfluoroethylmethylether CF3OC2F5, perfluorodimethylether CF3OCF3, as well as CF3OCF2OCF3 and fluoropolyethers CF3(OCF2)2OCF3, CF3(OCF2)3OCF3,and CF3(OCF2)4OCF3.
Patent PT-912155-E (PT)
Inventor: NEHMET LASZLO
IPC: C03C4/00
Filed: 1996-07-19
Abstract: Glass composition (I) comprising 70-75% SiO2, 12-18% B2O3,4-8% Na2O, 0.5-2.0% K2O, and 0.8-2.0% Al2O3.
Patent PT-923657-E (PT)
Inventor: BURROW THOMAS RICHARD
IPC: D06M11/00
Filed: 1997-09-02
Abstract: Fabric comprising yarns comprising lyocell fibres is treated with a swelling agent, preferably aqueous sodium hydroxide, whilst in a form in which it is unrestrained and free to shrink. The swelling agent causes the lyocell fibres to swell without destroying their structure by dissolution, the amount of swelling being in excess of the amount to which the lyocell fibres will swell during exposure to all subsequent wet processing of the fabric. The effect of the swelling agent is then diluted with water so as substantially to set the yarns in the fabric in the positions relative to one another that they have in the swollen condition. The resulting fabrics are very much less affected by creasing than untreated fabrics are and do not suffer as much from the formation of lines during subsequent wet processing.
Patent PT-951292-E (PT)
Title: Treating an ischemic disorder and improving stroke outcome
Inventor: STERN DAVID
IPC: A61K49/00
Filed: 1997-09-25
Abstract: The present invention provides for a method for treating an ischemic disorder in a subject with comprises administering to the subject a pharmaceutically acceptable form of a selection antagonist in a sufficient amount over a sufficient time period to prevent white blood cell accumulation so as to treat the ischemic disorder in the subject. The invention further provides a method for treating an ischemic disorder in a subject which comprises administering to the subject carbon monoxide gas in a sufficient amount over a sufficient period of time thereby treating the ischemic disorder in the subject. The invention further provides a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of inactivated Factor IX in a sufficient amount over a sufficient period of time to inhibit coagulation so as to treat the ischemic disorder in the subject.
Patent PT-846450-E (PT)
Inventor: ISRAEL HENRY M
IPC: A61M29/00
Filed: 1995-07-26
Abstract: The stent (30) is formed of a tube having a patterned shape which has first and second meander patterns having axes extending in first and second directions. The first meander patterns can be formed in even and odd first meander patterns. The even and odd first meander patterns are 180 deg. out of phase with each other, and the odd patterns occur between every two even patterns. The second meander patterns are intertwined with the first meander patterns. The first and second directions can be orthogonal to each other. The second meander patterns can also be formed of even and odd patterns.
Patent PT-996349-E (PT)
Inventor: FROMME HEINRICH
IPC: A47C23/04
Filed: 1998-07-17
Abstract: The invention relates to a bearing element having a base plate fitted on a support, for a seat or bed system, with a bearing plate to hold upholstery. The invention seeks to produce a bearing element whose range of spring is approximately equal to the total height, and which is easy to produce. To this end, at least two spring elements serving as bearing arms (12, 22) are fitted between the base plate (11, 21) and the bearing plate (15, 25). These spring elements, configured like leaf springs, are directed outwards from the base plate (11, 21). Their outer ends join the hearing plate (15, 25). In another version of the invention, a spring body (35, 35') is fitted between the base and bearing plate. The spring body head (35.2) and foot (35.1), like the bearing plate and base plate, have corresponding locking parts, so that the bearing plate can also be removably placed on the spring body (15, 15') and on the base plate (21). The invention also seeks to provide a bed system that is fitted with the inventive bearing elements, and which is characterized by its versatility. To this effect, fixing means for bearing elements are fitted on the plate or laths, preferably as undercrosses (30) that can be connected by socket connectors, with fixing means for the bearing element (10, 20) in the crossing area. A second version of the invention is intended in particular for lath frames (2) with mountable frame part(s) (3, 5, 7). In this version, at least one row of bearing elements (30') belonging to the outer mountable frame part is fitted with bearing elements (35') having a foot support (31) and a bearing plate (20, 40, 50). The other rows have bearing elements (30), which comprise a foot support (31), spring body (35, 35') and bearing plate (20, 40, 50).
Patent PT-1007932-E (PT)
Inventor: HEUFT BERNHARD
IPC: G01M3/36
Filed: 1998-08-25
Abstract: To test the features of containers (10) which are sealed by means of a closure (12), such as central fit of the closure (12) on the container opening, tightness of the fitting of the closure (12) or the residual air volume in containers (10) in which the liquid is foamed up before closure, in order to expel the residual air volume, mechanical vibrations are excited in the closure (10) and the mechanical vibrations are analysed. The mechanical vibrations are analysed directly after the closure (12) has been fitted, before major change in the pressure takes place in the container.
Patent PT-1028714-E (PT)
Inventor: OPPENHEIM RICHARD CHARLES
IPC: A61K9/48
Filed: 1998-11-06
Abstract: The invention disclosed herein includes a vitamin composition encapsulated in a soft or hard shell capsule, said vitamin composition comprising water soluble vitamin particles suspended in a fill liquid, wherein said water soluble vitamin particles are coated with a material that is substantially insoluble in the fill liquid and the shell of the capsule, but soluble in the gastrointestinal tract of a mammal, and the coated water soluble vitamin particles are of a size that are suitable for encapsulating as a suspension in said capsule. The invention also includes a process for manufacturing the same. Vitamin containing capsules according to this invention are discoloration-resistant.
Patent PT-1082125-E (PT)
Inventor: JEANJEAN MICHEL
IPC: A61P9/14
Filed: 1999-06-02
Abstract: The invention concerns a pharmaceutical or cosmetic composition, in particular for the hair, characterised in that it comprises in a suitable vehicle, an efficient dose of a Ruscus aculeatus extract stimulating the production of the vascular endothelial growth factor (VEGF). In an advantageous embodiment, the Ruscus aculeatus extract is a Ruscus aculeatus extract, in particular obtained by extracting the homogenate using a polar solvent end then recuperating the subsequent solution and concentration. The invention also concerns a pharmaceutical or cosmetic treatment of diseases related to angiogenic disorders, characterised in that it consists in applying a composition comprising a suitable vehicle and an efficient dose of Ruscus aculeatus extract stimulating the production of the vascular endothelial growth factor (VEGF).
Patent PT-1126848-E (PT)
Inventor: BROWN STEPHEN
IPC: A61K47/12
Filed: 1999-11-02
Abstract: A plastics container containing a sterile aqueous solution of an acid addition salt of a 1-alkyl-N-(2,6-dimethylphenyl)-2-piperidinecaboxamide, wherein the solution is buffered.
Patent SG-12993-G (SG)
Title: Process for decreasing the range of values of the mechanical chracteristics of tungsten-nickel-iron alloys
IPC: C22C1/04
Filed: 1993-02-06
Abstract: A process for reducing disparities of mechanical properties in tungsten-nickel-iron alloys containing in % by weight 85 to 99% of tunsten, 1 to 10% of iron, the alloys being obtained from tungsten, nickel and iron powders which have the same or different grain diameter, shape and size distribution, which entails simultaneously adding an effective amount of each of cobalt and manganese powders to tungsten powder or to a mixture of tungsten, nickel and iron powders.
Patent SG-44193-G (SG)
Title: Gasoline composition
IPC: C10L1/16
Filed: 1993-04-14
Abstract: Improved gasoline compositions containing a minor amount of a polyalphaolefin having a viscosity at 100 DEG C from 2 to 20 centistokes, and optionally also an aliphatic polyamine, an alkali or alkaline earth metal salt of a succinic acid derivative, and/or a polyolefin; together with a concentrate for the production of such gasoline composition and a method of operating a spark-ignition engine using such gasoline composition.
Patent IE-790005-L (IE)
Title: 4''-acylamino-4''-deoxy derivatives of oleandomycin,¹erythromycins a and b, and erythromycylamine
IPC: A61P31/04
Filed: 1979-01-02
Abstract: Derivatives of oleandomycin, erythromycin A and B, erythromycylamine and erythromycin carbonate, having at the 4''-position an acylamido group, their preparation and use as antibacterial agents are described.
[US4180654A]